DSGN earnings date and last-quarter result: last quarter beat, P/E -9.82. Updated 2026-07-23.
Design Therapeutics (DSGN) Research Hub
Design Therapeutics (DSGN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 10.34 USD (+0.98%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -9.82, market cap 0.73B. This hub links to the full technical, earnings and options research available for DSGN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 10.34 USD (+0.98%) |
| 52-week range | 9.47 USD – 16.12 USD |
| Trend regime | Range |
| 14-day RSI | 34.4 (Bearish) |
| Trailing P/E | -9.82 |
| Market cap | 0.73B |
| Dividend yield | 0.00% |
Available research for DSGN
Covered Call on DSGN: how it works, illustrative setup around the real 10.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DSGN: how it works, illustrative setup around the real 10.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DSGN: how it works, illustrative setup around the real 10.34 USD price, max profit/loss, breakeven and when to use it. Educational.
DSGN technical analysis: range, last 10.34 USD, RSI 34.4, 52w range 9.47 USD–16.12 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is DSGN in?
Design Therapeutics (DSGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DSGN in an uptrend or downtrend?
As of 2026-10-26, DSGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DSGN's trailing P/E ratio?
DSGN's trailing P/E is -9.82, with a market cap of 0.73B. See the earnings research page for full valuation detail.